In a study presented at ACTRIMS Forum 2023, researchers assessed pregnancy outcomes and disease activity following cladribine exposure in women with MS.

Researchers sought to evaluate the demographics and clinical presentation of patients with MOGAD-related optic neuritis in a Canadian population.

In a study presented at ACTRIMS Forum 2023, researchers assessed the efficacy of treatment regimens on disability outcomes of patients with NMOSD- and MOGAD-optic neuritis and myelitis.

In a study presented at ACTRIMS Forum 2023, researchers assessed the influence of drivers on clinician considerations when choosing S1P receptor modulators to treat patients with MS.

Researchers assessed the extent to which MS rehabilitation trials considered race and ethnicity in trial and intervention processes.

In a study presented at ACTRIMS Forum 2023, researchers identified MRI volumetric biomarkers associated with concurrent disability progression in MS.

In a study presented at ACTRIMS Forum 2023, researchers assessed the relationship between global and cortex-specific structures with cognitive performance in older patients with MS.

Researchers assessed the efficacy, safety, and tolerability of glatiramer acetate (GA) Depot when given every 4 weeks in patients with relapsing forms of MS.

Researchers sought to determine the effect of long-term depletion of CD19+ B cells on childhood vaccine-generated humoral responses in participants from N-Momentum.

Researchers sought to segment and detect active and nonactive white matter MS lesions via the development of a deep learning technique.